Pharmaron Beijing Co., Ltd.

SZSE:300759 Stock Report

Market Cap: CN¥44.4b

Pharmaron Beijing Past Earnings Performance

Past criteria checks 5/6

Pharmaron Beijing has been growing earnings at an average annual rate of 17.8%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 24.3% per year. Pharmaron Beijing's return on equity is 13%, and it has net margins of 16%.

Key information

17.8%

Earnings growth rate

16.4%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate24.3%
Return on equity13.0%
Net Margin16.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Pharmaron Beijing (SZSE:300759) Has A Somewhat Strained Balance Sheet

Dec 01
Pharmaron Beijing (SZSE:300759) Has A Somewhat Strained Balance Sheet

At CN¥29.44, Is It Time To Put Pharmaron Beijing Co., Ltd. (SZSE:300759) On Your Watch List?

Nov 15
At CN¥29.44, Is It Time To Put Pharmaron Beijing Co., Ltd. (SZSE:300759) On Your Watch List?

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Fly 29% But Investors Aren't Buying For Growth

Sep 27
Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Fly 29% But Investors Aren't Buying For Growth

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Could Be 22% Below Their Intrinsic Value Estimate

Sep 20
Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Could Be 22% Below Their Intrinsic Value Estimate

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) Intrinsic Value Is Potentially 69% Above Its Share Price

May 12
Pharmaron Beijing Co., Ltd.'s (SZSE:300759) Intrinsic Value Is Potentially 69% Above Its Share Price

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) 27% Share Price Surge Not Quite Adding Up

Mar 04
Pharmaron Beijing Co., Ltd.'s (SZSE:300759) 27% Share Price Surge Not Quite Adding Up

Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly

Feb 27
Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly

Revenue & Expenses Breakdown

How Pharmaron Beijing makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300759 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2411,7951,8841,888484
30 Jun 2411,5021,9281,895474
31 Mar 2411,4851,4831,883465
31 Dec 2311,5381,6011,895448
30 Sep 2311,4241,5531,966402
30 Jun 2311,2721,5751,950381
31 Mar 2310,8871,4741,887320
01 Jan 2310,2661,3751,749282
30 Sep 229,5451,5821,533219
30 Jun 228,7931,6821,355171
31 Mar 228,0571,6641,147162
31 Dec 217,4441,6611,033152
30 Sep 216,8491,423954146
30 Jun 216,2261,258856127
31 Mar 215,6641,317820113
31 Dec 205,1341,172761105
30 Sep 204,7171,00869189
30 Jun 204,31486563679
31 Mar 203,95359460575
31 Dec 193,75754757463
30 Sep 193,49943754751
30 Jun 193,27437852544
31 Mar 193,08934649834
31 Dec 182,90833346132
30 Sep 182,71330068646
31 Dec 172,29423137423
31 Dec 161,6341772800
31 Dec 151,128742210
31 Dec 14790211550

Quality Earnings: 300759 has high quality earnings.

Growing Profit Margin: 300759's current net profit margins (16%) are higher than last year (13.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300759's earnings have grown by 17.8% per year over the past 5 years.

Accelerating Growth: 300759's earnings growth over the past year (21.3%) exceeds its 5-year average (17.8% per year).

Earnings vs Industry: 300759 earnings growth over the past year (21.3%) exceeded the Life Sciences industry -14.4%.


Return on Equity

High ROE: 300759's Return on Equity (13%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 00:34
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharmaron Beijing Co., Ltd. is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Linda LuBOCI Research Ltd.
Yang LuoBOCI Research Ltd.
Bo LiBofA Global Research